Sun Pharmaceutical Industries is addressing regulatory issues at three facilities, including an import alert at Halol.

Sun Pharma is stepping up regulatory compliance efforts at three USFDA-flagged facilities, including Halol, Mohali, and Dadra.

Sun Pharma aims to enhance compliance and R&D investment for global speciality products, targeting mid to high single-digit ...

Sun Pharma is working to resolve USFDA compliance issues at three facilities: Halol, Mohali, and Dadra. The company is implementing CAPA and anticipates mid to high single-digit growth in FY26.

Sun Pharmaceutical Industries Ltd. closed 14.66% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

Mumbai: Sun Pharma Advanced Research Company Limited (SPARC) has announced the incorporation of its wholly owned subsidiary, ...

N ew Delhi: Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues, according to the US Food and Drug Administration (USFDA). The New Jersey-based ...

Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales.

Sun Pharma appoints Richard Ascroft as North America CEO to lead U.S. and Canada operations, including new drug launches and ...

Sun Pharmaceutical Industries Ltd. closed 14.47% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

NEW DELHI: Drug makers Glenmark, Sun Pharma and Zydus are recalling products in the US for manufacturing issues, the US Food and Drug Administration (USFDA) said in its latest Enforcement Report.